Anteris Technologies Global (AVR) Stock Price, News & Analysis

Company Overview

Anteris Technologies Global Ltd (NASDAQ: AVR) is a commercial-stage life sciences company specializing in advanced biomaterials and protective medical devices. The company’s core mission is to develop and deliver innovative solutions that address musculoskeletal and cardiovascular disorders. By leveraging proprietary biomaterial processing technologies, Anteris aims to improve both the safety profile and long-term performance of implantable devices used in clinical settings around the world.

One of Anteris’s flagship products is a noninvasive head-emphasizing device designed to reduce the risk and severity of mild traumatic brain injury in contact sports. In parallel, the company has established a tissue engineering platform for heart valve applications, utilizing a novel pericardial scaffold that seeks to enhance valve durability and biocompatibility. Anteris’s pipeline also includes next-generation soft tissue repair matrices intended for orthopedic and spinal surgery, where improved healing and reduced inflammatory response are key objectives.

Founded in 2012, Anteris Technologies Global maintains a dual presence in the United States and Australia, with research laboratories in Brisbane and a commercial office in Minneapolis. The company has navigated a series of regulatory milestones, securing CE mark approval in Europe and pursuing additional clearances in North America and Asia. Its global footprint allows it to collaborate with leading academic institutions and clinical trial sites across multiple continents.

Anteris’s leadership team brings together seasoned professionals from the medical device and biotechnology sectors, with expertise spanning biomedical engineering, regulatory affairs, and global commercial operations. The company has established partnerships with contract manufacturers and contract research organizations to support scalable production and streamline clinical development, positioning it for continued growth in the regenerative medicine and protective device markets.

Key Stats

• Today's Range: $2.85 to $3.00
• 50-Day Range: $2.90 to $5.37
• 52-Week Range: $2.34 to $8.79
• Volume: 119,411 shs
• Average Volume: 222,848 shs
• Market Capitalization: $107.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.50
• Consensus Rating: Buy

AVR Stock Analysis - Frequently Asked Questions

How have AVR shares performed this year?

Anteris Technologies Global's stock was trading at $5.58 at the start of the year. Since then, AVR stock has decreased by 47.5% and is now trading at $2.93.

How were Anteris Technologies Global's earnings last quarter?

Anteris Technologies Global Corp. (NASDAQ:AVR) announced its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.61) earnings per share (EPS) for the quarter.

When did Anteris Technologies Global IPO?

Anteris Technologies Global (AVR) raised $89 million in an IPO on Friday, December 13th 2024. The company issued 14,800,000 shares at $6.00 per share.

When did the company's lock-up period expire?

Anteris Technologies Global's lock-up period expired on Wednesday, June 11th. Anteris Technologies Global had issued 14,800,000 shares in its IPO on December 13th. The total size of the offering was $88,800,000 based on an initial share price of $6.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the expiration of the lock-up period.

How do I buy shares of Anteris Technologies Global?

Shares of AVR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:AVR
• Previous Symbol: NASDAQ:AVR
• CIK: 2011514
• Web: N/A
• Phone: (651) 493-0606
• Fax: N/A
• Employees: 138
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Anteris Technologies Global: $16.50
• High Price Target: $22.00
• Low Price Target: $9.00
• Potential Upside/Downside: +463.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.67
• Quick Ratio: 3.65

Sales & Book Value

• Annual Sales: $2.70 million
• Price / Sales: 39.13
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.74 per share
• Price / Book: 1.68

Miscellaneous

• Outstanding Shares: 36,060,000
• Free Float: N/A
• Market Cap: $105.66 million
• Optionable: N/A
• Beta: N/A